Nissen MD, the Chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic.
FORBES: Steven Nissen: The Hidden Agenda Behind The FDA's New Avandia Hearings
The study is "hugely important, " says Steven Nissen, chairman of the department of cardiovascular medicine at the Cleveland Clinic, who was not involved in the study.
WSJ: Mediterranean Diet of Olive Oil, Nuts, Reduces Heart Disease, Study Finds
Graham MacGregor, professor of cardiovascular medicine at The Wolfson Institute of Preventive Medicine, Queen Mary University and chairman of Cash, said that too much salt is harmful.
Nissen, the chairman of cardiovascular medicine at the Cleveland Clinic.
CNN: FDA considers statin use for those with normal cholesterol
Graham MacGregor, professor of cardiovascular medicine at Queen Mary, who led the study, said that the "modest reduction" in salt intake was equivalent to halving the amount of salt we consume each day.
Doctors may feel the drug provides little extra benefit compared with an existing heart failure drug, spironolactone, for a much higher cost, notes Eric Topol, chairman of cardiovascular medicine at the Cleveland Clinic.
Christopher Heeschen and Christian Hamm, of the department of cardiovascular medicine at Stanford University, California, also writing in The Lancet, said there are three possible reasons for the lack of benefit of sibrafiban.
The gift is believed to be largest philanthropic investment to advance cardiovascular medicine ever reported in the United States.. In return for the favor, the university has decided to name the new cardiovascular institute the OHSU Knight Cardiovascular Institute.
Steven Nissen, chairman of cardiovascular medicine at the Cleveland Clinic, who has run clinical trials on many important heart medicines but is perhaps best known for raising red flags on drug safety, including on Vioxx, now withdrawn, and Avandia, which has had its use severely limited.
History may be repeating itself as Sankyo develops a new medicine for cardiovascular disease.
"This is the first gene-targeted medicine in cardiovascular disease, " says Cleveland Clinic's Topol, who is helping design the trial.
Topol himself has written that a second Celebrex trial would be necessary to know for sure that the medicine causes cardiovascular damage, even though its safety is questionable.
Earlier today I summarized the important new PREDIMED study published in the New England Journal of Medicine showing the cardiovascular benefits of the Mediterranean diet.
"If people come in and say my chest hurts, that gets attention, but if they say my leg hurts when I walk a couple of blocks, most doctors don't think that is a big deal, " says William Hiatt, professor of cardiovascular research at the University of Colorado School of Medicine and chairman of the American Heart Association's Peripheral Vascular Disease Council.
WSJ: Peripheral Artery Disease (PAD) - When Achy Legs Are a Warning
Then there's the new medical study in the Journal of Occupational and Environment Medicine at Columbia University that looks into the cardiovascular health of business travellers.
The researchers, writing in the Archives of Internal Medicine, found aspirin reduced the risk of cardiovascular disease by 10% but this was offset by a 30% increase in the risk of serious internal bleeds.
The upside to its story, he says, comes as the company transitions from the current cosmetic-and-reconstructive surgery approach to regenerative medicine specifically in the area of both acute and chronic cardiovascular disease.
FORBES: Human Body's Fat Seen As best Source of Stem Cells For Regenerative Therapies
In fact, it is running what could be the definitive test of fish oil-based drugs: a study of whether adding Vascepa to a statin medicine in patients with high triglycerides reduces the risk of cardiovascular disease.
FORBES: Could A Fish Oil Backlash Wash Out Amarin Pharmaceuticals?
The New England Journal of Medicine released internal Merck memos indicating that Merck knew more about cardiovascular problems caused by Vioxx than it revealed when it published a giant study of the drug in 2000.
The two-year-old start-up seeks to combine evidence-based medicine, behavioral modification techniques and smart design to combat major illnesses, such as diabetes, and cardiovascular disease before they become full-blown.
FORBES: Omada Health Which Focuses On Diabetes Prevention Raises $4.7 Million
应用推荐